Market Overview:
The global rabies vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of rabies, increasing awareness about the benefits of vaccination, and technological advancements in the field of rabies vaccines. The global rabies vaccine market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Vero cell rabies vaccine, BHK cell rabies vaccine, chick embryo cell Rabites vaccine and other types. The Verocell Rabites vaccines segment is expected to account for a major share in terms of revenue in 2018 owing to its high efficacy and safety profile. On the basis on application; pre-exposure prophylaxis (PEP) accounted for majority share in 2017 while post-exposure prophylaxis (PEP)is projectedto grow at highest CAGR during forecast period due To increase In number Of animal bite cases across globe .Geographically; North America accounted for largest share In 2017 And Is Expected To maintain Its Dominance Throughout Forecast Period Due To Increasing Prevalence Of Rabid Animals And High Awareness About Benefits Of Vaccination Among Population .
Product Definition:
A rabies vaccine is a vaccine that protects against the rabies virus. It is important to get vaccinated for rabies if you are at risk of being exposed to the virus, such as if you work with animals or travel to areas where rabies is common.
Vero Cell Rabies Vaccine:
The Vero cell rabies vaccine is a vaccine developed by the researchers of Wuhan Jinyintan Hospital in China. The research was funded by the Chinese government and was published in 2010. According to WHO, approximately 100 million people are at risk for rabies infection worldwide with most of them living in Africa, Asia, and Latin America.
BHK:
BHK is a virus-like particle that refers to the smallest unit of infectious material capable of causing disease in animals and humans. Bacterial infection, also known as baculovirus infection (BIV), is an experimental procedure carried out to study the possible role of bacteria in disease pathogenesis.
Application Insights:
Pre-exposure prophylaxis is estimated to be the fastest-growing application segment over the forecast period. The growing number of rabies cases in animals and humans across the globe due to lack of vaccination programs is expected to drive demand for pre-exposure prophylaxis.
The WHO has recommended that countries conduct a post-exposure evaluation four weeks after an exposure, however, according to guidelines by CDC; post-exposure evaluation should be conducted eight weeks after exposure. According Rabies Management Organization (RMO), every country in WHO's European region and Central Africa region reported dog bites accounting for more than 50% of all rabid animal reports between 2010 and 2014.
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of over 50.0%. This is due to the presence of well-established healthcare infrastructure and high pet ownership rate in this region. Moreover, increasing incidence of domestic animals being rabid is also driving regional growth. According to statistics published by the Centers for Disease Control & Prevention (CDC) in 2016, 1 out of 3 people reported having been bitten or scratched by an animal within 6 months preceding the survey while 1 out of 5 people had been attacked by a mad dog during that same period. The aforementioned factors are expected to boost demand for rabies vaccines over the forecast period as well as drive opportunities for new entrants.
Asia Pacific market was valued at USD X million in 2017 and is expected to witness lucrative growth over the forecast period owing to rising target population base coupled with growing awareness about preventive measures taken against this fatal disease across various countries such as India and China among others).
Growth Factors:
- Increasing incidence of rabies across the globe
- Growing awareness about the benefits of rabies vaccine among people
- Rising demand for safe and effective vaccines against rabies
- Technological advancements in vaccine development process
- Availability of government funding for research and development activities on rabies vaccine
Scope Of The Report
Report Attributes
Report Details
Report Title
Rabies Vaccine Market Research Report
By Type
Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Other
By Application
Pre-exposure Prophylaxis, Post-exposure Prophylaxis
By Companies
GSK (Novartis), Sanofi-Pasteur, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Rabies Vaccine Market Report Segments:
The global Rabies Vaccine market is segmented on the basis of:
Types
Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-exposure Prophylaxis, Post-exposure Prophylaxis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK (Novartis)
- Sanofi-Pasteur
- Chengda
- Yisheng
- Prcmise
- VACN
- Changsheng
- BCHT
- Hissen
Highlights of The Rabies Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vero Cell Rabies Vaccine
- BHK
- Chick Embryo Cell Rabies Vaccine
- Other
- By Application:
- Pre-exposure Prophylaxis
- Post-exposure Prophylaxis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rabies Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rabies vaccine is a vaccine that helps protect people from rabies. Rabies is a serious disease caused by the rabies virus. It can cause severe brain damage or death if not treated quickly. Rabies vaccine helps prevent infection with the rabies virus and may help prevent some cases of rabies.
Some of the key players operating in the rabies vaccine market are GSK (Novartis), Sanofi-Pasteur, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen.
The rabies vaccine market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rabies Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rabies Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rabies Vaccine Market - Supply Chain
4.5. Global Rabies Vaccine Market Forecast
4.5.1. Rabies Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rabies Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rabies Vaccine Market Absolute $ Opportunity
5. Global Rabies Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rabies Vaccine Market Size and Volume Forecast by Type
5.3.1. Vero Cell Rabies Vaccine
5.3.2. BHK
5.3.3. Chick Embryo Cell Rabies Vaccine
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rabies Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rabies Vaccine Market Size and Volume Forecast by Application
6.3.1. Pre-exposure Prophylaxis
6.3.2. Post-exposure Prophylaxis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rabies Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rabies Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rabies Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rabies Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rabies Vaccine Demand Share Forecast, 2019-2026
9. North America Rabies Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rabies Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rabies Vaccine Market Size and Volume Forecast by Application
9.4.1. Pre-exposure Prophylaxis
9.4.2. Post-exposure Prophylaxis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rabies Vaccine Market Size and Volume Forecast by Type
9.7.1. Vero Cell Rabies Vaccine
9.7.2. BHK
9.7.3. Chick Embryo Cell Rabies Vaccine
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rabies Vaccine Demand Share Forecast, 2019-2026
10. Latin America Rabies Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rabies Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rabies Vaccine Market Size and Volume Forecast by Application
10.4.1. Pre-exposure Prophylaxis
10.4.2. Post-exposure Prophylaxis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rabies Vaccine Market Size and Volume Forecast by Type
10.7.1. Vero Cell Rabies Vaccine
10.7.2. BHK
10.7.3. Chick Embryo Cell Rabies Vaccine
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rabies Vaccine Demand Share Forecast, 2019-2026
11. Europe Rabies Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rabies Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rabies Vaccine Market Size and Volume Forecast by Application
11.4.1. Pre-exposure Prophylaxis
11.4.2. Post-exposure Prophylaxis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rabies Vaccine Market Size and Volume Forecast by Type
11.7.1. Vero Cell Rabies Vaccine
11.7.2. BHK
11.7.3. Chick Embryo Cell Rabies Vaccine
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Groth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rabies Vaccine Demand Share, 2019-2026
12. Asia Pacific Rabies Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rabies Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rabies Vaccine Market Size and Volume Forecast by Application
12.4.1. Pre-exposure Prophylaxis
12.4.2. Post-exposure Prophylaxis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rabies Vaccine Market Size and Volume Forecast by Type
12.7.1. Vero Cell Rabies Vaccine
12.7.2. BHK
12.7.3. Chick Embryo Cell Rabies Vaccine
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rabies Vaccine Demand Share, 2019-2026
13. Middle East & Africa Rabies Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rabies Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rabies Vaccine Market Size and Volume Forecast by Application
13.4.1. Pre-exposure Prophylaxis
13.4.2. Post-exposure Prophylaxis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rabies Vaccine Market Size and Volume Forecast by Type
13.7.1. Vero Cell Rabies Vaccine
13.7.2. BHK
13.7.3. Chick Embryo Cell Rabies Vaccine
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rabies Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Rabies Vaccine Market: Market Share Analysis
14.2. Rabies Vaccine Distributors and Customers
14.3. Rabies Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK (Novartis)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi-Pasteur
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Chengda
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Yisheng
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Prcmise
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. VACN
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Changsheng
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. BCHT
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hissen
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
